Harbin Pharma Holdings To Acquire Sanjing Pharma For RMB 5.5 Billion
This article was originally published in PharmAsia News
Executive Summary
Harbin Pharmaceutical Holdings plans to acquire bioengineering company Sanjing Pharmaceutical of Harbin Pharmaceutical, HPH's parent company, for a total of RMB 5.5 billion ($0.838 billion)